Zhongzhi Pharmaceutical Group signed an industry-university-research cooperation agreement with the Macau University of Science and Technology (MUST) on August 25 during the 4th Guangdong-Hong Kong-Macao Greater Bay Area Chinese Medicine Inheritance Innovation and Development Conference. 

The two sides have previously established cooperation in terms of scientific researches and personnel exchanges on the research and development of medicinal materials in Lingnan areas and built a joint laboratory for the study on the quality of traditional Chinese medicine.

Zhongzhi Pharmaceutical Group is a large-scale pharmaceutical industry and trade enterprise specializing in the R&D, production and marketing of Chinese patent medicine, TCM decoction pieces, healthcare products and related food as well as a pharmaceutical retail chain enterprise. It is a headquarters enterprise in Zhongshan and also the largest domestic enterprise on the R&D and production of cell wall-broken decoction pieces used in traditional Chinese medicine.

The MUST has established a national key lab on TCM quality research, which is dedicated to the integration of multi-disciplinary cutting-edge technologies to carry out integrative, innovative research on traditional Chinese medicine. It mainly focuses on innovative techniques and methods on the quality control and optimization of TCM materials and Chinese herbal compound prescription, as well as key technologies and quality standards on the R&D of new traditional chinese medicine.